Recently, the Hong Kong market has experienced volatility, with the Hang Seng Index down 2.11%, reflecting broader economic challenges and changes in investor sentiment. In this environment, high-growth tech stocks such as Tencent Holdings have attracted attention for their potential to effectively navigate these dynamics, offering investors an opportunity in an innovation-driven sector.
name
increase in revenue
revenue growth
growth assessment
Wasion Holdings
22.37%
25.47%
★★★★★☆
Medsai Healthcare Holdings
48.74%
48.78%
★★★★★☆
Inspur Digital Enterprise Technology
23.30%
38.78%
★★★★★☆
remegen
26.23%
52.03%
★★★★★☆
Cowell E Holdings
31.68%
35.44%
★★★★★
Innovent Biologics
22.11%
59.31%
★★★★★☆
Akiso
33.50%
53.12%
★★★★★
Biocytogen Pharmaceuticals (Beijing)
21.53%
109.17%
★★★★★☆
beijing air dock technology
37.47%
93.35%
★★★★★☆
Sichuan Cologne-Biotech Biopharmaceutical
24.70%
8.53%
★★★★★☆
Click here to see the complete list of 43 stocks in the SEHK High Growth Technology Stock and AI Stock Screener.
Let’s take a look at some noteworthy stocks from the screened stocks.
Simply Wall Street Growth Rating: ★★★★☆
Overview: Tencent Holdings Limited is an investment holding company that provides value-added services, online advertising, fintech and business services in China and around the world, with a market capitalization of approximately HK$3.87 trillion.
Business Operations: Tencent generates significant revenue with CAD 302.28 billion from value-added services (VAS) and CAD 209.17 billion from fintech and business services. Online advertising also plays an important role, with revenue reaching CAD 111.89 billion.
Tencent Holdings is pursuing strategic mergers and acquisitions amid a difficult market, and in particular is considering partnering to acquire Ubisoft. The move could stabilize the latter’s declining value and increase Tencent’s influence in the gaming sector. On the financial front, Tencent showed solid growth, with sales in the first half of 2024 increasing to 320.62 billion yuan from 299.19 billion yuan in the previous year, recording a higher increase than many domestic peers. Additionally, revenue increased by more than 72% to RMB 89.52 billion, reflecting strong operational efficiency and strategic investments that may strengthen future growth prospects in both domestic and international markets. .
SEHK:700 profit and revenue growth as of October 2024
Simply Wall Street Growth Rating: ★★★★☆
Overview: Lenovo Group Limited is an investment holding company that develops, manufactures and sells technology products and services with a market capitalization of approximately HK$139.18 billion.
story continues
Business Operations: The company primarily generates revenue through the Intelligent Devices Group (IDG), which accounts for $45.76 billion, followed by the Infrastructure Solutions Group (ISG), which accounts for $10.17 billion, and the Solutions and Services Group (SSG), which accounts for $10.17 billion. ) is $7.64 billion.
Lenovo Group is making great strides in integrating AI into a variety of technology solutions, as evidenced by our recent collaboration with Red Hat to optimize AI computing on Lenovo ThinkSystem servers. This partnership underscores Lenovo’s commitment to strengthening AI infrastructure as the industry increasingly relies on high-performance computing for AI applications. The company’s R&D spending is strong, with a consistent reinvestment rate of 7.9% of revenue in R&D. This reflects a deliberate strategy to foster innovation and remain competitive in the high-tech market. Additionally, Lenovo’s revenue is expected to grow 18.7% annually, highlighting the company’s potential resilience and adaptability in a rapidly evolving technology environment.
SEHK:992 revenue and revenue growth (as of October 2024)
Simply Wall Street Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of antibody therapeutics with a market capitalization of HK$59.24 billion.
What it does: The company primarily generates revenue from research, development, production and sales of biopharmaceuticals, amounting to C$1.87 billion.
Akeso is making waves in Hong Kong’s high-growth technology sector, particularly with the recent breakthrough results of the COMPASSION-16 study on cervical cancer treatment. The company’s commitment to innovation is evidenced by the fact that it reinvests a significant portion of its revenues into research and development, maintaining an annual spend rate of 33.5%. This strategic focus drives expected revenue growth of 53.1% and positions Akeso uniquely among its peers in the advancement of biotechnology. Furthermore, the successful HK$1.94 billion equity issue confirms market confidence and strengthens our financial capacity to sustain active research activities, promising a strong pipeline and potential market expansion.
SEHK:9926 Breakdown of revenue and expenses as of October 2024
Let’s take a closer look at all 43 SEHK high-growth technology and AI stocks we’ve identified here.
Are you already investing in these stocks? Stay on top of every twist and turn by setting up your portfolio with Simply Wall St. This makes it easier for investors like you to stay informed and proactive.
Invest smarter with the free Simply Wall St app, which provides detailed insights into every stock market in the world.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies covered in this article include SEHK:700 SEHK:992 and SEHK:9926.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.
